2026 / 01

Next Paper
DOI: 10.24075/dc.2026.003
Copyright: © 2026 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Design and study of the BIODISTRIBUTION OF LEAD COMPOUNDS FROM THE SYDNONIMINE GROUP

Popov NS1 , Gavrilenko DA1 , Baranov MS2,3 , Kaurova DE2 , Myasnyanko IN2,3 , Balabanyan VYu2 , Ivanov DS3
About authors

1 Tver State Medical University, Tver, Russia

2 Pirogov Russian National Research Medical University, Moscow, Russia

3 Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia

Correspondence should be addressed: Nikita S Popov
Sovetskaya St., 4, Tver, 170100, Russia; ur.liam@vopop.sn

About paper

Financing: The study was carried out within the framework of a state assignment, the research topic: “Development of a drug candidate with predominantly central vasodilatory action for the treatment of cerebrovascular pathologies”, state registration number — 124020900020-4.

Author contribution: Popov NS — development of the bioanalytical method, conducting pharmacokinetic studies, manuscript preparation; Gavrilenko DA — conducting pharmacokinetic studies, manuscript preparation; Baranov MS — synthesis of sydnonimine group compounds, manuscript preparation; Balabanyan VYu — defining the aim, developing the study design, manuscript preparation; Kaurova DE — literature review, manuscript preparation; Myasnyanko IN — synthesis of sydnonimine group compounds, manuscript preparation. All authors made an equal contribution to the preparation of the publication and confirm that their authorship meets the international ICMJE criteria, Ivanov DS — synthesis of compounds of the sydnone imine group, preparation of the manuscript.

Compliance with ethical standards: The study was approved by the Ethics Committee of Tver State Medical University of the Ministry of Health of Russia (Protocol No. 5 dated June 19, 2024). All experiments were performed in accordance with the Rules of Laboratory Practice (Order of the Ministry of Health of Russia No. 708n dated August 23, 2010, Directive 2010/63/EU of the European Parliament and of the Council on the protection of vertebrate animals used for scientific purposes).

Received: 2026-02-16 Accepted: 2026-03-25 Published online: 2026-03-13
|
  1. Khan T, Yadav R, Kesharwani AK, & Chourasia K. A review on synthesis, characterization, and pharmacological properties of some sydnone derivatives. Mini-Reviews in Organic Chemistry. 2025; 22(4): 359–380. DOI: 10.2174/1570193X21666230831153810
  2. Idocin AF, Specklin S, & Taran F. Sydnonimines: synthesis, properties and applications in chemical biology. Chemical Communications. 2025; 61(31): 5704–5718. DOI: 10.1039/ D5CC00535C.
  3. Fershtat LL, & Zhilin ES. Recent advances in the synthesis and biomedical applications of heterocyclic NO-donors. Molecules. 2021; 26(18): 5705. DOI: 10.3390/molecules26185705
  4. Hossain SL, Mathews M, Nagarajappa VSB, Kumar BK, Yelamaggad CVV, & Singh R. Antiproliferative, apoptosis-inducing activity and molecular docking studies of sydnones compounds. Journal of Cancer Research and Therapeutics. 2022; 18(3): 681– 690. DOI: 10.4103/jcrt.JCRT_1614_20.
  5. Pétry N, Luttringer F, Bantreil X, & Lamaty F. A mechanochemical approach to the synthesis of sydnones and derivatives. Faraday Discussions. 2023; 241: 114–127. DOI: 10.1039/D2FD00096B.
  6. Srivastava SK, Singh SP, & Rao DP. Synthesis of Mesoionic 1-aryl-4-(phenyl/p-chlorophenyl) imidazo [2, 1-b] thiazol-4-ones and Study of their Monoamine Oxidase, Succinate Dehydrogenase Inhibitory, Anti-convulsant, and Antibacterial Activity. 2022. DOI: 10.33263/LIANBS123.090.
  7. Shuvaev AD, Zhilin ES, & Fershtat LL. NOBF4-Mediated Assembly of the Sydnone Imine Scaffold in the Synthesis of Double Nitric Oxide Donors. Synthesis. 2023; 55(12): 1863–1874. DOI: 10.1055/a-2011-7264.
  8. Yoon H, Park S, & Lim M. Dynamics of irreversible NO release from photoexcited Molsidomine. The Journal of Physical Chemistry Letters. 2023; 14(2): 516–523. DOI: 10.1021/acs.jpclett.2c03613.
  9. Khmel’nitskaya EY, Levina VI, Trukhacheva LA, Grigoriev NB, Kalinin VN, Cherepanov IA, … & Granik VG. Sydnonimines as exogenous NO donors. Russian chemical bulletin. 2004; 53(12): 2840–2844. DOI: 10.1007/s11172-005-0199-2.
  10. Chepur SV. Combat Stress: Formation Mechanisms and Targets of Directed Pharmacological Effects. Human Physiology. 2024; 50(6): 657–663. DOI: 10.1134/S0362119724701123.
  11. An JM, Moon SA, Hong SY, Kang JW, & Seo JT. Neuroprotective effect of 3-morpholinosydnonimine against Zn2+-induced PC12 cell death. European Journal of Pharmacology. 2015; 748: 37–44. DOI: 10.1016/j.ejphar.2014.12.003.
  12. Utkina-Sosunova I, Chiorazzi A, de Planell-Saguer M, Li H, Meregalli C, Pozzi E, & Lotti F. Molsidomine provides neuroprotection against vincristine-induced peripheral neurotoxicity through soluble guanylyl cyclase activation. Scientific reports. 2024; 14(1): 19341. DOI: 10.1038/s41598-024-70294-w.
  13. Barcelos MP, Gomes SQ, Federico LB, Francischini IAG, Hage-Melim LID S., Silva G M, & de Paula da Silva CHT. Lead optimization in drug discovery. In Research topics in bioactivity, environment and energy: experimental and theoretical tools. 2022; 481–500. Cham: Springer International Publishing. DOI: 10.1007/978-3-031-07622-0_19.
  14. Verma S, & Pathak RK. Discovery and optimization of lead molecules in drug designing. In Bioinformatics. 2022; 253–267. Academic Press. DOI: 10.1016/B978-0-323-89775-4.00004-3
  15. Popov NS, Terekhov VM, Baranov MS, Balabanyan VY, Kaurova DE, Myasnyank IN & Terekhova EA. In vivo assessment of the role of liver metabolism in sydnone imine biotransformation. Bulletin of Russian State Medical University. 2025; (3): 46–52. DOI: 10.24075/brsmu.2025.026.
  16. Popov NS, Gavrilenko DA, Pavlov RD, Baranov MS, Kaurova DE, Myasnyanko IN, Ivanov DS & Balabanyan VY. Study of the biotransformation of a new sydnonimine derivative with predominant cerebral vasodilatory activity. Research Results in Pharmacology. 2025; 11(4): 258–271.DOI:10.18413/rrpharmacology.11.1042